Soleno Therapeutics, Inc. (SLNO) NASDAQ

87.08

+2.215(+2.61%)

Updated at July 31 12:49PM

Currency In USD

Soleno Therapeutics, Inc.

Address

203 Redwood Shores Parkway

Redwood City, CA 94065

United States of America

Phone

650 213 8444

Sector

Healthcare

Industry

Biotechnology

Employees

115

First IPO Date

November 13, 2014

Key Executives

NameTitlePayYear Born
Dr. Anish Bhatnagar M.D.Chairman, President, Chief Executive Officer & Chief Operating Officer1.05M1970
Ms. Kristen Yen M.S.Senior Vice President of Global Clinical Operations and Patient Advocacy317,1901969
Ms. Patricia C. Hirano M.P.H.Senior Vice President of Regulatory Affairs515,8131966
Ms. Meredith Manning M.B.A.Chief Commercial Officer605,1611972
Mr. James H. MacKanessChief Financial Officer & Compliance Officer656,2001964
Dr. Neil M. Cowen M.B.A., Ph.D.Senior Vice President of Drug Development0N/A
Dr. Michael Huang M.D.Senior Vice President of Clinical Development01974
Dr. Mitchell Nagao M.B.A., Pharm.D.Senior Vice President of Medical Affairs0N/A
Ms. Lauren BudesheimVice President of People0N/A
Mr. Jesse SchumakerGeneral Counsel0N/A

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.